Xconomy | Seattle - Business + Technology in the Exponential Economy

CMC Icos to Make Lung Drug

CMC Icos Biologics, the Bothell, WA-based contract manufacturer of biotech drugs, said today it has signed a deal to manufacture an experimental drug for acute lung injury. CMC will make IC14, an antibody drug, for Brisbane, Australia-based Implicit Bioscience. The treatment, which is scheduled to enter Phase II trials next year, was previously tested in 150 patients by Icos for its potential against inflammatory diseases.

Luke Timmerman is the National Biotechnology Editor for Xconomy. You can e-mail him at ltimmerman@xconomy.com, call 206-624-2374, or follow him on Twitter at http://twitter.com/ldtimmerman.

Comments | Reprints | Share: